Novartis Ag (NVS) 93.91 $NVS
Vanda Gains Fanapt Rights from Novartis for the U.S. Region - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:30PM CST
Vanda Pharmaceuticals Inc. (VNDA) recently announced that it has reached a settlement agreement with Novartis AG (Novartis) related to Fanapt.
BIIB: 340.89 (+5.13), VNDA: 14.69 (+1.11), SHPG: 209.29 (+0.07), NVS: 93.91 (+0.66)
Heard on the Street: New Research on American Airlines, Novo Nordisk, Novartis, DIRECTV and Sony
PR Newswire - Wed Dec 24, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including American Airlines (NASDAQ: AAL), Novo Nordisk (NYSE: NVO), Novartis (NYSE: NVS), DIRECTV (NASDAQ: DTV), and Sony (NYSE: SNE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
NVO: 43.80 (+1.08), DTV: 86.82 (-0.05), SNE: 21.32 (+0.46), AAL: 51.43 (+1.22), NVS: 93.91 (+0.66)
The Global Defenders
Eric Parnell, CFA - at Seeking Alpha - Wed Dec 24, 12:25AM CST
BUD: 115.51 (+0.09), EIS: 46.92 (-0.19), UN: 39.92 (+0.05), UL: 41.49 (+0.09), EWN: 24.48 (+0.15), GSK: 42.85 (+0.11), XLU: 47.97 (+0.87), EWL: 32.34 (+0.14), DEO: 116.91 (+0.98), EWK: 16.58 (+0.08), XLV: 68.64 (+0.50), XLP: 49.38 (-0.05), IYZ: 29.52 (-0.18), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), NVO: 43.80 (+1.08), AZN: 70.44 (+0.26), ENZL: 39.52 (+0.22), EWU: 18.39 (+0.15), TEVA: 57.09 (+0.33), ACWX: 43.59 (+0.24), EDEN: 48.09 (+0.18), NGG: 72.20 (+1.11), NVS: 93.91 (+0.66)
Vanda rises on settlement
at Investor's Business Daily - Tue Dec 23, 5:48PM CST
The biotech settled a lawsuit with Novartis (NVS) over its schizophrenia drug Fanapt. Late Mon., Vanda (VNDA) said its Big Pharma partner had agreed to transfer U.S. and Canadian rights of Fanapt and make a $25 mil equity investment in the firm....
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Watch for Novartis to Potentially Rebound After Falling 2.15% Yesterday
Comtex SmarTrend(R) - Tue Dec 23, 4:31PM CST
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $92.85 to a high of $94.83. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $93.43 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 93.91 (+0.66)
Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)
Vanda Pops After Regaining Drug Rights
at Investor's Business Daily - Tue Dec 23, 11:44AM CST
Shares of biotech Vanda Therapeutics (VNDA) soared nearly 25% at one point on the stock market today, to an almost five-month high, after the company settled a lawsuit with its Big Pharma partner and regained full rights to schizophrenia drug Fanapt....
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Stock Futures Jump On GDP Data; Walgreen, NQ Mobile Advance
at Investor's Business Daily - Tue Dec 23, 8:10AM CST
Stock futures stepped up early gains, pointing firmly higher Tuesday, after Q3 GDP growth estimates came in higher than expected. Dow futures doubled their early gains to trade 86.6 points above fair market value. Nasdaq 100 futures jumped 18.1...
JRJC: 5.81 (-0.11), VNDA: 14.69 (+1.11), MARA: 9.32 (-0.35), NQ: 4.32 (-0.36), WAG: 76.67 (+0.16), NVS: 93.91 (+0.66)
EC clears expanded label for Alcon glaucoma med
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 6:20AM CST
NVS: 93.91 (+0.66)
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 88.76 (+3.23), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07), EXEL: 1.29 (-0.01)
Vanda to regain US and Canadian rights to the atypical antipsychotic agent Fanapt
M2 - Tue Dec 23, 5:22AM CST
Biopharmaceutical company Vanda Pharmaceuticals (NasdaqGM:VNDA) and Novartis AG announced Monday an agreement to dismiss the ongoing Fanapt arbitration proceedings and to release each other from any related claims.
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Mylan reports market availability of first generic Vivelle-DOT for vasomotor symptoms & vulvar and vaginal atrophy
M2 - Tue Dec 23, 5:22AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Tuesday that it has unveiled its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (twice weekly) in the market.
MYL: 56.97 (+0.39), NVS: 93.91 (+0.66)
Alcon treatment Travatan(R) receives EU approval for pediatric glaucoma patients
Thomson Reuters ONE - Tue Dec 23, 12:15AM CST
Novartis International AG / Alcon treatment Travatan(R) receives EU approval for pediatric glaucoma patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 93.91 (+0.66)
Vanda and Novartis settle license spat
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 3:26PM CST
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Vanda to regain US and Canadian rights to Fanapt®
PR Newswire - Mon Dec 22, 3:01PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has reached a settlement agreement with Novartis AG (Novartis) related to the ongoing Fanapt® license arbitration proceedings. The parties have agreed to dismiss the ongoing Fanapt® arbitration and to release each other from any related claims. As a part of the settlement agreement, Novartis will (i) transfer all US and Canadian rights in the Fanapt® franchise to Vanda, (ii) make a $25 million equity investment in Vanda at a price per share equal to $13.82 and (iii) grant to Vanda an exclusive worldwide license to AQW051, a phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Hold On To Teva!
Investing Tricks - at Seeking Alpha - Mon Dec 22, 2:09PM CST
MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66)
Lilly jettisons Sentinel line as a condition for clearance of Novartis deal
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:32AM CST
LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)
Missed the Juno IPO? Take a Look at MabVax
ACCESSWIRE - Mon Dec 22, 8:33AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / When an initial public offering soars over 50% right out of the gate, you almost never get a second chance to buy at the IPO price. Juno Therapeutics (NASDAQ:JUNO), an oncology-focused biotech not even a year and a half old, accomplished just that on Friday when it offered shares at $24 a piece and closed its first trading day just below $37.
JUNO: 39.99 (+2.71), NVS: 93.91 (+0.66)
Mylan Launches First Generic Version of Vivelle-DOT®
PR Newswire - Mon Dec 22, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), which is the generic version of Novartis' Vivelle-DOT®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis.(1)
MYL: 56.97 (+0.39), NVS: 93.91 (+0.66)
Vanda Gains Fanapt Rights from Novartis for the U.S. Region - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:30PM CST
Vanda Pharmaceuticals Inc. (VNDA) recently announced that it has reached a settlement agreement with Novartis AG (Novartis) related to Fanapt.
BIIB: 340.89 (+5.13), VNDA: 14.69 (+1.11), SHPG: 209.29 (+0.07), NVS: 93.91 (+0.66)
Heard on the Street: New Research on American Airlines, Novo Nordisk, Novartis, DIRECTV and Sony
PR Newswire - Wed Dec 24, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including American Airlines (NASDAQ: AAL), Novo Nordisk (NYSE: NVO), Novartis (NYSE: NVS), DIRECTV (NASDAQ: DTV), and Sony (NYSE: SNE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
NVO: 43.80 (+1.08), DTV: 86.82 (-0.05), SNE: 21.32 (+0.46), AAL: 51.43 (+1.22), NVS: 93.91 (+0.66)
The Global Defenders
Eric Parnell, CFA - at Seeking Alpha - Wed Dec 24, 12:25AM CST
BUD: 115.51 (+0.09), EIS: 46.92 (-0.19), UN: 39.92 (+0.05), UL: 41.49 (+0.09), EWN: 24.48 (+0.15), GSK: 42.85 (+0.11), XLU: 47.97 (+0.87), EWL: 32.34 (+0.14), DEO: 116.91 (+0.98), EWK: 16.58 (+0.08), XLV: 68.64 (+0.50), XLP: 49.38 (-0.05), IYZ: 29.52 (-0.18), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), NVO: 43.80 (+1.08), AZN: 70.44 (+0.26), ENZL: 39.52 (+0.22), EWU: 18.39 (+0.15), TEVA: 57.09 (+0.33), ACWX: 43.59 (+0.24), EDEN: 48.09 (+0.18), NGG: 72.20 (+1.11), NVS: 93.91 (+0.66)
Vanda rises on settlement
at Investor's Business Daily - Tue Dec 23, 5:48PM CST
The biotech settled a lawsuit with Novartis (NVS) over its schizophrenia drug Fanapt. Late Mon., Vanda (VNDA) said its Big Pharma partner had agreed to transfer U.S. and Canadian rights of Fanapt and make a $25 mil equity investment in the firm....
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Watch for Novartis to Potentially Rebound After Falling 2.15% Yesterday
Comtex SmarTrend(R) - Tue Dec 23, 4:31PM CST
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $92.85 to a high of $94.83. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $93.43 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVS: 93.91 (+0.66)
Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)
Vanda Pops After Regaining Drug Rights
at Investor's Business Daily - Tue Dec 23, 11:44AM CST
Shares of biotech Vanda Therapeutics (VNDA) soared nearly 25% at one point on the stock market today, to an almost five-month high, after the company settled a lawsuit with its Big Pharma partner and regained full rights to schizophrenia drug Fanapt....
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Stock Futures Jump On GDP Data; Walgreen, NQ Mobile Advance
at Investor's Business Daily - Tue Dec 23, 8:10AM CST
Stock futures stepped up early gains, pointing firmly higher Tuesday, after Q3 GDP growth estimates came in higher than expected. Dow futures doubled their early gains to trade 86.6 points above fair market value. Nasdaq 100 futures jumped 18.1...
JRJC: 5.81 (-0.11), VNDA: 14.69 (+1.11), MARA: 9.32 (-0.35), NQ: 4.32 (-0.36), WAG: 76.67 (+0.16), NVS: 93.91 (+0.66)
EC clears expanded label for Alcon glaucoma med
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 6:20AM CST
NVS: 93.91 (+0.66)
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 88.76 (+3.23), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07), EXEL: 1.29 (-0.01)
Vanda to regain US and Canadian rights to the atypical antipsychotic agent Fanapt
M2 - Tue Dec 23, 5:22AM CST
Biopharmaceutical company Vanda Pharmaceuticals (NasdaqGM:VNDA) and Novartis AG announced Monday an agreement to dismiss the ongoing Fanapt arbitration proceedings and to release each other from any related claims.
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Mylan reports market availability of first generic Vivelle-DOT for vasomotor symptoms & vulvar and vaginal atrophy
M2 - Tue Dec 23, 5:22AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Tuesday that it has unveiled its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (twice weekly) in the market.
MYL: 56.97 (+0.39), NVS: 93.91 (+0.66)
Alcon treatment Travatan(R) receives EU approval for pediatric glaucoma patients
Thomson Reuters ONE - Tue Dec 23, 12:15AM CST
Novartis International AG / Alcon treatment Travatan(R) receives EU approval for pediatric glaucoma patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 93.91 (+0.66)
Vanda and Novartis settle license spat
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 3:26PM CST
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Vanda to regain US and Canadian rights to Fanapt®
PR Newswire - Mon Dec 22, 3:01PM CST
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has reached a settlement agreement with Novartis AG (Novartis) related to the ongoing Fanapt® license arbitration proceedings. The parties have agreed to dismiss the ongoing Fanapt® arbitration and to release each other from any related claims. As a part of the settlement agreement, Novartis will (i) transfer all US and Canadian rights in the Fanapt® franchise to Vanda, (ii) make a $25 million equity investment in Vanda at a price per share equal to $13.82 and (iii) grant to Vanda an exclusive worldwide license to AQW051, a phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
VNDA: 14.69 (+1.11), NVS: 93.91 (+0.66)
Hold On To Teva!
Investing Tricks - at Seeking Alpha - Mon Dec 22, 2:09PM CST
MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66)
Lilly jettisons Sentinel line as a condition for clearance of Novartis deal
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:32AM CST
LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)
Missed the Juno IPO? Take a Look at MabVax
ACCESSWIRE - Mon Dec 22, 8:33AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / When an initial public offering soars over 50% right out of the gate, you almost never get a second chance to buy at the IPO price. Juno Therapeutics (NASDAQ:JUNO), an oncology-focused biotech not even a year and a half old, accomplished just that on Friday when it offered shares at $24 a piece and closed its first trading day just below $37.
JUNO: 39.99 (+2.71), NVS: 93.91 (+0.66)
Mylan Launches First Generic Version of Vivelle-DOT®
PR Newswire - Mon Dec 22, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), which is the generic version of Novartis' Vivelle-DOT®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis.(1)
MYL: 56.97 (+0.39), NVS: 93.91 (+0.66)
